SE|15996060||ti|1|text|172|317|Sex hormone concentrations in patients with rheumatoid arthritis are not       normalized during 12 weeks of anti-tumor necrosis factor therapy.
SE|15996060||ti|1|entity|C0036884|Gonadal Steroid Hormones|horm|||Sex hormone|||0|901|172|183
SE|15996060||ti|1|entity|C0030705|Patients|podg|||patients|||0|1000|202|210
SE|15996060||ti|1|entity|C0003873|Rheumatoid Arthritis|dsyn|||rheumatoid arthritis|||0|1000|216|236
SE|15996060||ti|1|entity|C1518422|Not|ftcn|||not|||0|1000|241|244
SE|15996060||ti|1|entity|C0439230|week|tmco|||weeks|||0|861|272|277
SE|15996060||ti|1|entity|C0281481|anti-tumor necrosis factor therapy|topp|||anti-tumor necrosis factor therapy|||0|1000|281|315
SE|15996060||ti|1|relation|0|0|C0036884|Gonadal Steroid Hormones|horm|horm|||Sex hormone|||0|901|172|183|INFER|TREATS(INFER)||199|201|0|0|C0003873|Rheumatoid Arthritis|dsyn|dsyn|||rheumatoid arthritis|||0|1000|216|236
SE|15996060||ti|1|relation|1|1|C0036884|Gonadal Steroid Hormones|horm|horm|||Sex hormone|||0|901|172|183|PREP|TREATS||199|201|4|1|C0030705|Patients|podg,humn|podg|||patients|||0|1000|202|210
SE|15996060||ti|1|relation|3|1|C0003873|Rheumatoid Arthritis|dsyn|dsyn|||rheumatoid arthritis|||0|1000|216|236|PREP|PROCESS_OF||211|215|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|202|210

SE|15996060|OBJECTIVE|ab|1|text|336|525|OBJECTIVE: Androgens such as dehydroepiandrosterone sulfate (DHEAS) and       testosterone are markedly lower in postmenopausal women with rheumatoid       arthritis (RA) than in controls.
SE|15996060|OBJECTIVE|ab|1|entity|C0002844|Androgens|horm,phsu|||Androgens|||0|1000|347|356
SE|15996060|OBJECTIVE|ab|1|entity|C0057277|Dehydroepiandrosterone Sulfate|bacs,phsu,strd|||dehydroepiandrosterone sulfate|||0|1000|365|395
SE|15996060|OBJECTIVE|ab|1|entity|C0039601|Testosterone|horm,phsu,strd|||testosterone|||0|1000|414|426
SE|15996060|OBJECTIVE|ab|1|entity|C0522501|Massive|qlco|||markedly|||0|888|431|439
SE|15996060|OBJECTIVE|ab|1|entity|C0441994|Lower|ftcn|||lower|||0|888|440|445
SE|15996060|OBJECTIVE|ab|1|entity|C0043210|Woman|popg|||women|||0|861|464|469
SE|15996060|OBJECTIVE|ab|1|entity|C0003873|Rheumatoid Arthritis|dsyn|||rheumatoid       arthritis|||0|1000|475|501
SE|15996060|OBJECTIVE|ab|1|entity|C0243148|control|ftcn|||controls|||0|966|515|523
SE|15996060|OBJECTIVE|ab|1|relation|0|0|C0039601|Testosterone|horm,phsu,strd|horm|||testosterone|||0|1000|414|426|SPEC|ISA||347|395|0|0|C0002844|Androgens|horm,phsu|horm|||Androgens|||0|1000|347|356
SE|15996060|OBJECTIVE|ab|1|relation|0|0|C0039601|Testosterone|horm,phsu,strd|phsu|||testosterone|||0|1000|414|426|INFER|TREATS(INFER)||446|448|0|0|C0003873|Rheumatoid Arthritis|dsyn|dsyn|||rheumatoid       arthritis|||0|1000|475|501
SE|15996060|OBJECTIVE|ab|1|relation|0|0|C0057277|Dehydroepiandrosterone Sulfate|bacs,phsu,strd|bacs|||dehydroepiandrosterone sulfate|||0|1000|365|395|SPEC|ISA||347|395|0|0|C0002844|Androgens|horm,phsu|horm|||Androgens|||0|1000|347|356
SE|15996060|OBJECTIVE|ab|1|relation|0|0|C0057277|Dehydroepiandrosterone Sulfate|bacs,phsu,strd|phsu|||dehydroepiandrosterone sulfate|||0|1000|365|395|INFER|TREATS(INFER)||446|448|0|0|C0003873|Rheumatoid Arthritis|dsyn|dsyn|||rheumatoid       arthritis|||0|1000|475|501
SE|15996060|OBJECTIVE|ab|1|relation|2|1|C0003873|Rheumatoid Arthritis|dsyn|dsyn|||rheumatoid       arthritis|||0|1000|475|501|PREP|PROCESS_OF||470|474|6|1|C0043210|Woman|popg,humn|humn|||women|||0|861|464|469
SE|15996060|OBJECTIVE|ab|1|relation|5|2|C0039601|Testosterone|horm,phsu,strd|phsu|||testosterone|||0|1000|414|426|PREP|TREATS||446|448|3|1|C0043210|Woman|popg,humn|popg|||women|||0|861|464|469
SE|15996060|OBJECTIVE|ab|1|relation|5|2|C0057277|Dehydroepiandrosterone Sulfate|bacs,phsu,strd|phsu|||dehydroepiandrosterone sulfate|||0|1000|365|395|PREP|TREATS||446|448|3|1|C0043210|Woman|popg,humn|popg|||women|||0|861|464|469

SE|15996060|OBJECTIVE|ab|2|text|525|633|In contrast, compared to controls, serum       levels of estrogens are normal or elevated in women with RA.
SE|15996060|OBJECTIVE|ab|2|entity|C0243148|control|ftcn|||controls|||0|966|550|558
SE|15996060|OBJECTIVE|ab|2|entity|C0229671|Serum|bdsu|||serum|||0|888|560|565
SE|15996060|OBJECTIVE|ab|2|entity|C0441889|Levels|inpr|||levels|||0|888|572|578
SE|15996060|OBJECTIVE|ab|2|entity|C0014939|Estrogens|horm,phsu,strd|||estrogens|||0|1000|582|591
SE|15996060|OBJECTIVE|ab|2|entity|C0205307|Normal|qlco|||normal|||0|1000|596|602
SE|15996060|OBJECTIVE|ab|2|entity|C0043210|Woman|popg|||women|||0|1000|618|623
SE|15996060|OBJECTIVE|ab|2|entity|C0003873|Rheumatoid Arthritis|dsyn|||RA|||0|1000|629|631
SE|15996060|OBJECTIVE|ab|2|relation|0|0|C0014939|Estrogens|horm,phsu,strd|phsu|||estrogens|||0|1000|582|591|INFER|TREATS(INFER)||615|617|0|0|C0003873|Rheumatoid Arthritis|dsyn|dsyn|||RA|||0|1000|629|631
SE|15996060|OBJECTIVE|ab|2|relation|1|1|C0003873|Rheumatoid Arthritis|dsyn|dsyn|||RA|||0|1000|629|631|PREP|PROCESS_OF||624|628|6|1|C0043210|Woman|popg,humn|humn|||women|||0|1000|618|623
SE|15996060|OBJECTIVE|ab|2|relation|5|2|C0014939|Estrogens|horm,phsu,strd|phsu|||estrogens|||0|1000|582|591|PREP|TREATS||615|617|2|1|C0043210|Woman|popg,humn|popg|||women|||0|1000|618|623

SE|15996060|OBJECTIVE|ab|3|text|633|844|Since tumor       necrosis factor (TNF) alters production of these hormones, we investigated       changes of these hormones during anti-TNF antibody (anti-TNF) therapy with       adalimumab in longstanding RA.
SE|15996060|OBJECTIVE|ab|3|entity|C0041368|Tumor Necrosis Factors|aapp,imft|7124|TNF|tumor       necrosis factor|||0|1000|639|666
SE|15996060|OBJECTIVE|ab|3|entity|C0033268|production|ocac|||production|||0|1000|680|690
SE|15996060|OBJECTIVE|ab|3|entity|C0019932|Hormones|horm|||hormones|||0|1000|700|708
SE|15996060|OBJECTIVE|ab|3|entity|C0019932|Hormones|horm|||hormones|||0|1000|749|757
SE|15996060|OBJECTIVE|ab|3|entity|C0041368|Tumor Necrosis Factors|aapp,imft|7124|TNF|TNF|||0|882|770|773
SE|15996060|OBJECTIVE|ab|3|entity|C0003242|Antibodies, Anti-Idiotypic|aapp,imft|||anti-TNF antibody|||0|882|765|782
SE|15996060|OBJECTIVE|ab|3|entity|C0041368|Tumor Necrosis Factors|aapp,imft|7124|TNF|TNF|||0|923|789|792
SE|15996060|OBJECTIVE|ab|3|entity|C0087111|Therapeutic procedure|topp|||therapy|||0|1000|794|801
SE|15996060|OBJECTIVE|ab|3|entity|C1122087|adalimumab|aapp,imft,phsu|||adalimumab|||0|1000|813|823
SE|15996060|OBJECTIVE|ab|3|entity|C0003873|Rheumatoid Arthritis|dsyn|||RA|||0|901|840|842
SE|15996060|OBJECTIVE|ab|3|relation|1|1|C0041368|Tumor Necrosis Factors|aapp,gngm,imft|aapp|7124|TNF|tumor       necrosis factor|||0|1000|639|666|VERB|INTERACTS_WITH||673|679|9|2|C0019932|Hormones|horm|horm|||hormones|||0|1000|700|708
SE|15996060|OBJECTIVE|ab|3|relation|5|1|C0019932|Hormones|horm|horm|||hormones|||0|1000|749|757|PREP|COEXISTS_WITH||758|764|5|1|C0003242|Antibodies, Anti-Idiotypic|aapp,gngm,imft|aapp|||anti-TNF antibody|||0|882|765|782
SE|15996060|OBJECTIVE|ab|3|relation|8|1|C0087111|Therapeutic procedure|topp|topp|||therapy|||0|1000|794|801|PREP|USES||802|806|2|1|C1122087|adalimumab|aapp,gngm,imft,phsu|aapp|||adalimumab|||0|1000|813|823

SE|15996060|METHODS|ab|4|text|844|1180|METHODS: In this longitudinal anti-TNF       therapy study in 13 patients with long-standing RA without prior       prednisolone (7 infusions of anti-TNF: Week 0, 2, 4, 6, 8, 10, and 12), we       measured serum concentrations of interleukin 6 (IL-6), androstenedione,       DHEA, DHEAS, free testosterone, estrone, and 17ss-estradiol.
SE|15996060|METHODS|ab|4|entity|C0025663|Methods|inpr|||METHODS|||0|1000|844|851
SE|15996060|METHODS|ab|4|entity|C0281481|anti-tumor necrosis factor therapy|topp|||anti-TNF       therapy|||0|909|874|896
SE|15996060|METHODS|ab|4|entity|C0023981|Longitudinal Studies|qnco,resa|||longitudinal anti-TNF       therapy study|||0|909|861|902
SE|15996060|METHODS|ab|4|entity|C0030705|Patients|podg|||patients|||0|861|909|917
SE|15996060|METHODS|ab|4|entity|C0205166|Long|qlco|||long|||0|861|923|927
SE|15996060|METHODS|ab|4|entity|C0231472|Orthostatic body position|spco|||standing|||0|861|928|936
SE|15996060|METHODS|ab|4|entity|C0003873|Rheumatoid Arthritis|dsyn|||RA|||0|861|937|939
SE|15996060|METHODS|ab|4|entity|C0332152|Status pre-|tmco|||prior|||1|888|948|953
SE|15996060|METHODS|ab|4|entity|C0032950|prednisolone|phsu,strd|||prednisolone|||1|888|960|972
SE|15996060|METHODS|ab|4|entity|C0574032|Infusion procedures|topp|||infusions|||0|827|976|985
SE|15996060|METHODS|ab|4|entity|C0041368|Tumor Necrosis Factors|aapp,imft|7124|TNF|TNF|||0|923|994|997
SE|15996060|METHODS|ab|4|entity|C0439230|week|tmco|||Week|||0|861|999|1003
SE|15996060|METHODS|ab|4|entity|C0683149|serum drug concentration|qnco|||serum concentrations|||0|983|1050|1070
SE|15996060|METHODS|ab|4|entity|C0021760|Interleukin-6|aapp,imft|||interleukin 6|||0|1000|1074|1087
SE|15996060|METHODS|ab|4|entity|C0002860|Androstenedione|horm,phsu,strd|||androstenedione|||0|1000|1096|1111
SE|15996060|METHODS|ab|4|entity|C0011185|dehydroepiandrosterone|horm,phsu,strd|||DHEA|||0|1000|1119|1123
SE|15996060|METHODS|ab|4|entity|C0057277|Dehydroepiandrosterone Sulfate|bacs,phsu,strd|||DHEAS|||0|1000|1125|1130
SE|15996060|METHODS|ab|4|entity|C0443483|Free testosterone|horm,strd|||free testosterone|||0|1000|1132|1149
SE|15996060|METHODS|ab|4|entity|C0014942|Estrone|horm,phsu,strd|||estrone|||0|1000|1151|1158
SE|15996060|METHODS|ab|4|entity|C0014912|Estradiol|horm,phsu,strd|||estradiol|||0|861|1169|1178
SE|15996060|METHODS|ab|4|relation|0|0|C0023981|Longitudinal Studies|qnco,resa|resa|||longitudinal anti-TNF       therapy study|||0|909|861|902|MOD/HEAD|USES||874|902|0|0|C0281481|anti-tumor necrosis factor therapy|topp|topp|||anti-TNF       therapy|||0|909|874|896
SE|15996060|METHODS|ab|4|relation|7|6|C0023981|Longitudinal Studies|qnco,resa|resa|||longitudinal anti-TNF       therapy study|||0|909|861|902|VERB|MEASURES||1041|1049|7|1|C0683149|serum drug concentration|qnco|qnco|||serum concentrations|||0|983|1050|1070
SE|15996060|METHODS|ab|4|relation|11|1|C0003873|Rheumatoid Arthritis|dsyn|dsyn|||RA|||0|861|937|939|PREP|PROCESS_OF||918|922|3|1|C0030705|Patients|podg,humn|humn|||patients|||0|861|909|917

SE|15996060|METHODS|ab|5|text|1180|1303|Levels of       these hormones in patients were compared to serum levels of 31 age and sex       matched healthy controls.
SE|15996060|METHODS|ab|5|entity|C0441889|Levels|inpr|||Levels|||0|1000|1180|1186
SE|15996060|METHODS|ab|5|entity|C0019932|Hormones|horm|||hormones|||0|1000|1202|1210
SE|15996060|METHODS|ab|5|entity|C0030705|Patients|podg|||patients|||0|1000|1214|1222
SE|15996060|METHODS|ab|5|entity|C0229671|Serum|bdsu|||serum|||0|888|1240|1245
SE|15996060|METHODS|ab|5|entity|C0441889|Levels|inpr|||levels|||0|888|1246|1252
SE|15996060|METHODS|ab|5|entity|C0001779|Age|orga|||age|||0|861|1259|1262
SE|15996060|METHODS|ab|5|entity|C0150103|MATCHING|resa|||matched|||0|808|1277|1284
SE|15996060|METHODS|ab|5|entity|C1456614|Sexual Health|clna|||sex       matched healthy|||0|808|1267|1292
SE|15996060|METHODS|ab|5|entity|C0243148|control|ftcn|||controls|||0|808|1293|1301
SE|15996060|METHODS|ab|5|relation|2|1|C0019932|Hormones|horm|horm|||hormones|||0|1000|1202|1210|PREP|TREATS||1211|1213|4|1|C0030705|Patients|podg,humn|podg|||patients|||0|1000|1214|1222

SE|15996060|RESULTS|ab|6|text|1303|1482|RESULTS: Upon treatment with anti-TNF, there was       an impressive decrease of clinical markers of inflammation, erythrocyte       sedimentation rate, and serum levels of IL-6.
SE|15996060|RESULTS|ab|6|entity|C1274040|result|ftcn|||RESULTS|||0|966|1303|1310
SE|15996060|RESULTS|ab|6|entity|C0087111|Therapeutic procedure|topp|||treatment|||0|1000|1317|1326
SE|15996060|RESULTS|ab|6|entity|C0041368|Tumor Necrosis Factors|aapp,imft|7124|TNF|TNF|||0|923|1337|1340
SE|15996060|RESULTS|ab|6|entity|C0547047|Decrease|qnco|||decrease|||0|861|1372|1380
SE|15996060|RESULTS|ab|6|entity|C0008963|Markers, Clinical|qlco|||clinical markers|||0|1000|1384|1400
SE|15996060|RESULTS|ab|6|entity|C0021368|Inflammation|patf|||inflammation|||0|1000|1404|1416
SE|15996060|RESULTS|ab|6|entity|C0086250|Erythrocyte Sedimentation Rate|celf|||erythrocyte       sedimentation rate|||0|1000|1418|1454
SE|15996060|RESULTS|ab|6|entity|C0229671|Serum|bdsu|||serum|||0|888|1460|1465
SE|15996060|RESULTS|ab|6|entity|C0441889|Levels|inpr|||levels|||0|888|1466|1472
SE|15996060|RESULTS|ab|6|entity|C0021760|Interleukin-6|aapp,imft|||IL-6|||0|1000|1476|1480
SE|15996060|RESULTS|ab|6|relation|2|1|C0087111|Therapeutic procedure|topp|topp|||treatment|||0|1000|1317|1326|PREP|USES||1327|1331|6|1|C0041368|Tumor Necrosis Factors|aapp,gngm,imft|aapp|7124|TNF|TNF|||0|923|1337|1340

SE|15996060|RESULTS|ab|7|text|1482|1653|Serum levels of DHEAS and       free testosterone were markedly lower at baseline in patients compared to       controls, but this did not change during anti-TNF therapy.
SE|15996060|RESULTS|ab|7|entity|C0229671|Serum|bdsu|||Serum|||0|888|1482|1487
SE|15996060|RESULTS|ab|7|entity|C0441889|Levels|inpr|||levels|||0|888|1488|1494
SE|15996060|RESULTS|ab|7|entity|C0057277|Dehydroepiandrosterone Sulfate|bacs,phsu,strd|||DHEAS|||0|1000|1498|1503
SE|15996060|RESULTS|ab|7|entity|C0443483|Free testosterone|horm,strd|||free testosterone|||0|1000|1514|1531
SE|15996060|RESULTS|ab|7|entity|C0522501|Massive|qlco|||markedly|||0|888|1537|1545
SE|15996060|RESULTS|ab|7|entity|C0441994|Lower|ftcn|||lower|||0|888|1546|1551
SE|15996060|RESULTS|ab|7|entity|C1442488|BASELINE|qnco|||baseline|||0|1000|1555|1563
SE|15996060|RESULTS|ab|7|entity|C0030705|Patients|podg|||patients|||0|1000|1567|1575
SE|15996060|RESULTS|ab|7|entity|C0243148|control|ftcn|||controls|||0|966|1594|1602
SE|15996060|RESULTS|ab|7|entity|C1518422|Not|ftcn|||not|||0|1000|1617|1620
SE|15996060|RESULTS|ab|7|entity|C0281481|anti-tumor necrosis factor therapy|topp|||anti-TNF therapy|||0|1000|1635|1651
SE|15996060|RESULTS|ab|7|relation|5|3|C0057277|Dehydroepiandrosterone Sulfate|bacs,phsu,strd|strd|||DHEAS|||0|1000|1498|1503|PREP|TREATS||1564|1566|3|1|C0030705|Patients|podg,humn|podg|||patients|||0|1000|1567|1575
SE|15996060|RESULTS|ab|7|relation|5|3|C0443483|Free testosterone|horm,strd|horm|||free testosterone|||0|1000|1514|1531|PREP|TREATS||1564|1566|3|1|C0030705|Patients|podg,humn|podg|||patients|||0|1000|1567|1575

SE|15996060|RESULTS|ab|8|text|1653|1848|Serum levels of       DHEA and 17ss-estradiol were significantly elevated in patients compared       to controls, but similarly, anti-TNF therapy did not change initially       increased levels.
SE|15996060|RESULTS|ab|8|entity|C0229671|Serum|bdsu|||Serum|||0|888|1653|1658
SE|15996060|RESULTS|ab|8|entity|C0441889|Levels|inpr|||levels|||0|888|1659|1665
SE|15996060|RESULTS|ab|8|entity|C0011185|dehydroepiandrosterone|horm,phsu,strd|||DHEA|||0|1000|1675|1679
SE|15996060|RESULTS|ab|8|entity|C0014912|Estradiol|horm,phsu,strd|||estradiol|||0|861|1689|1698
SE|15996060|RESULTS|ab|8|entity|C0030705|Patients|podg|||patients|||0|1000|1730|1738
SE|15996060|RESULTS|ab|8|entity|C0243148|control|ftcn|||controls|||0|966|1757|1765
SE|15996060|RESULTS|ab|8|entity|C0281481|anti-tumor necrosis factor therapy|topp|||anti-TNF therapy|||0|1000|1782|1798
SE|15996060|RESULTS|ab|8|entity|C1518422|Not|ftcn|||not|||0|1000|1803|1806
SE|15996060|RESULTS|ab|8|entity|C0205265|Initially|tmco|||initially|||1|851|1814|1823
SE|15996060|RESULTS|ab|8|entity|C0205217|Increased|qnco|||increased|||1|851|1830|1839
SE|15996060|RESULTS|ab|8|entity|C0441889|Levels|inpr|||levels|||1|851|1840|1846
SE|15996060|RESULTS|ab|8|relation|3|1|C0011185|dehydroepiandrosterone|horm,phsu,strd|horm|||DHEA|||0|1000|1675|1679|PREP|TREATS||1727|1729|4|1|C0030705|Patients|podg,humn|podg|||patients|||0|1000|1730|1738
SE|15996060|RESULTS|ab|8|relation|3|1|C0014912|Estradiol|horm,phsu,strd|horm|||estradiol|||0|861|1689|1698|PREP|TREATS||1727|1729|4|1|C0030705|Patients|podg,humn|podg|||patients|||0|1000|1730|1738

SE|15996060|RESULTS|ab|9|text|1848|2032|Molar ratios of hormones, which reflect hormone shifts       via converting enzymes, showed typical alterations at baseline, but did       not change markedly during anti-TNF therapy.
SE|15996060|RESULTS|ab|9|entity|C1610540|Kind of quantity - Ratios|qnco|||ratios|||0|861|1854|1860
SE|15996060|RESULTS|ab|9|entity|C0019932|Hormones|horm|||hormones|||0|1000|1864|1872
SE|15996060|RESULTS|ab|9|entity|C0019932|Hormones|horm|||hormone|||0|1000|1888|1895
SE|15996060|RESULTS|ab|9|entity|C1550513|via|idcn|||via|||0|802|1909|1912
SE|15996060|RESULTS|ab|9|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|802|1924|1931
SE|15996060|RESULTS|ab|9|entity|C1515926|Alteration|idcn|||alterations|||0|827|1948|1959
SE|15996060|RESULTS|ab|9|entity|C1442488|BASELINE|qnco|||baseline|||0|1000|1963|1971
SE|15996060|RESULTS|ab|9|entity|C1518422|Not|ftcn|||not|||0|1000|1987|1990
SE|15996060|RESULTS|ab|9|entity|C0522501|Massive|qlco|||markedly|||1|1000|1998|2006
SE|15996060|RESULTS|ab|9|entity|C0281481|anti-tumor necrosis factor therapy|topp|||anti-TNF therapy|||0|1000|2014|2030

SE|15996060|CONCLUSION|ab|10|text|2032|2217|CONCLUSION: Longterm therapy       with anti-TNF did not change altered serum levels of typical sex hormones       in patients with RA, although baseline values were largely different.
SE|15996060|CONCLUSION|ab|10|entity|C0087111|Therapeutic procedure|topp|||therapy|||0|861|2053|2060
SE|15996060|CONCLUSION|ab|10|entity|C0041368|Tumor Necrosis Factors|aapp,imft|7124|TNF|TNF|||0|923|2077|2080
SE|15996060|CONCLUSION|ab|10|entity|C1518422|Not|ftcn|||not|||0|1000|2085|2088
SE|15996060|CONCLUSION|ab|10|entity|C0205349|Altered|ftcn|||altered|||1|851|2096|2103
SE|15996060|CONCLUSION|ab|10|entity|C0229671|Serum|bdsu|||serum|||0|851|2104|2109
SE|15996060|CONCLUSION|ab|10|entity|C0441889|Levels|inpr|||levels|||0|851|2110|2116
SE|15996060|CONCLUSION|ab|10|entity|C0036884|Gonadal Steroid Hormones|horm|||sex hormones|||0|901|2128|2140
SE|15996060|CONCLUSION|ab|10|entity|C0030705|Patients|podg|||patients|||0|1000|2150|2158
SE|15996060|CONCLUSION|ab|10|entity|C0003873|Rheumatoid Arthritis|dsyn|||RA|||0|1000|2164|2166
SE|15996060|CONCLUSION|ab|10|entity|C1442488|BASELINE|qnco|||baseline|||0|888|2177|2185
SE|15996060|CONCLUSION|ab|10|entity|C0042295|Values|qlco|||values|||0|888|2186|2192
SE|15996060|CONCLUSION|ab|10|entity|C1547020|*Difference|qnco|||different|||0|789|2206|2215
SE|15996060|CONCLUSION|ab|10|relation|0|0|C0036884|Gonadal Steroid Hormones|horm|horm|||sex hormones|||0|901|2128|2140|INFER|TREATS(INFER)||2147|2149|0|0|C0003873|Rheumatoid Arthritis|dsyn|dsyn|||RA|||0|1000|2164|2166
SE|15996060|CONCLUSION|ab|10|relation|2|1|C0087111|Therapeutic procedure|topp|topp|||therapy|||0|861|2053|2060|PREP|USES||2067|2071|7|1|C0041368|Tumor Necrosis Factors|aapp,gngm,imft|aapp|7124|TNF|TNF|||0|923|2077|2080
SE|15996060|CONCLUSION|ab|10|relation|3|1|C0003873|Rheumatoid Arthritis|dsyn|dsyn|||RA|||0|1000|2164|2166|PREP|PROCESS_OF||2159|2163|6|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|2150|2158
SE|15996060|CONCLUSION|ab|10|relation|5|1|C0036884|Gonadal Steroid Hormones|horm|horm|||sex hormones|||0|901|2128|2140|PREP|TREATS||2147|2149|4|1|C0030705|Patients|podg,humn|podg|||patients|||0|1000|2150|2158

SE|15996060|CONCLUSION|ab|11|text|2217|2421|In       patients with RA, this indicates that alterations of sex hormones and       altered activity of respective converting enzymes are imprinted for a       long-lasting period over at least 12 weeks.
SE|15996060|CONCLUSION|ab|11|entity|C0030705|Patients|podg|||patients|||0|1000|2226|2234
SE|15996060|CONCLUSION|ab|11|entity|C0003873|Rheumatoid Arthritis|dsyn|||RA|||0|1000|2240|2242
SE|15996060|CONCLUSION|ab|11|entity|C1515926|Alteration|idcn|||alterations|||0|966|2264|2275
SE|15996060|CONCLUSION|ab|11|entity|C0036884|Gonadal Steroid Hormones|horm|||sex hormones|||0|1000|2279|2291
SE|15996060|CONCLUSION|ab|11|entity|C0205349|Altered|ftcn|||altered|||0|888|2302|2309
SE|15996060|CONCLUSION|ab|11|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|827|2344|2351
SE|15996060|CONCLUSION|ab|11|entity|C0205166|Long|qlco|||long|||0|763|2378|2382
SE|15996060|CONCLUSION|ab|11|entity|C0439531|/period|tmco|||period|||0|763|2391|2397
SE|15996060|CONCLUSION|ab|11|entity|C0439230|week|tmco|||weeks|||0|827|2415|2420
SE|15996060|CONCLUSION|ab|11|relation|7|1|C0003873|Rheumatoid Arthritis|dsyn|dsyn|||RA|||0|1000|2240|2242|PREP|PROCESS_OF||2235|2239|1|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|2226|2234

SE|167592||ti|1|text|171|295|Control of hepatic glycogen metabolism in the rhesus monkey: effect of glucose,       insulin, and glucagon administration.
SE|167592||ti|1|entity|C0243148|control|ftcn|||Control|||0|1000|171|178
SE|167592||ti|1|entity|C0017911|Glycogen|bacs,carb|||glycogen|||0|901|190|198
SE|167592||ti|1|entity|C1373178|Hepatic Metabolism|ortf|||hepatic glycogen metabolism|||0|901|182|209
SE|167592||ti|1|entity|C0024400|Macaca mulatta|mamm|||rhesus monkey|||0|1000|217|230
SE|167592||ti|1|entity|C1280500|Effect|qlco|||effect|||0|1000|232|238
SE|167592||ti|1|entity|C0017725|Glucose|bacs,carb,phsu|||glucose|||0|1000|242|249
SE|167592||ti|1|entity|C0021641|Insulin|aapp,horm,phsu|||insulin|||0|1000|257|264
SE|167592||ti|1|entity|C0017687|Glucagon|aapp,horm,nsba,phsu|2641|GCG|glucagon|||0|888|270|278
SE|167592||ti|1|relation|2|1|C1373178|Hepatic Metabolism|ortf|ortf|||hepatic glycogen metabolism|||0|901|182|209|PREP|PROCESS_OF||210|212|5|1|C0024400|Macaca mulatta|mamm|mamm|||rhesus monkey|||0|1000|217|230
SE|167592||ti|1|relation|6|5|C0017687|Glucagon|aapp,gngm,horm,nsba,phsu|aapp|2641|GCG|glucagon|||0|888|270|278|NOM|AFFECTS||171|178|6|1|C1373178|Hepatic Metabolism|ortf|ortf|||hepatic glycogen metabolism|||0|901|182|209
SE|167592||ti|1|relation|6|5|C0017725|Glucose|bacs,carb,phsu|phsu|||glucose|||0|1000|242|249|NOM|AFFECTS||171|178|6|1|C1373178|Hepatic Metabolism|ortf|ortf|||hepatic glycogen metabolism|||0|901|182|209
SE|167592||ti|1|relation|6|5|C0021641|Insulin|aapp,gngm,horm,phsu|aapp|||insulin|||0|1000|257|264|NOM|AFFECTS||171|178|6|1|C1373178|Hepatic Metabolism|ortf|ortf|||hepatic glycogen metabolism|||0|901|182|209

SE|167592||ab|1|text|312|516|The effects of intravenous glucose, insulin and glucagon admininistration on the        hepatic glycogen synthase and glycogen phosphorylase systems were assessed in the       anesthetized rhesus monkey.
SE|167592||ab|1|entity|C1280500|Effect|qlco|||effects|||0|966|316|323
SE|167592||ab|1|entity|C0357164|Parenteral form glucose|carb,phsu|||intravenous glucose|||0|1000|327|346
SE|167592||ab|1|entity|C0021641|Insulin|aapp,horm,phsu|||insulin|||0|1000|348|355
SE|167592||ab|1|entity|C0017687|Glucagon|aapp,horm,nsba,phsu|2641|GCG|glucagon|||0|694|360|368
SE|167592||ab|1|entity|C0205054|Hepatic|blor|||hepatic|||0|901|400|407
SE|167592||ab|1|entity|C0017932|Glycogen (Starch) Synthase|aapp,enzy|||glycogen synthase|||0|901|408|425
SE|167592||ab|1|entity|C0917785|Glycogen Phosphorylase|aapp,enzy|||glycogen phosphorylase|||0|901|430|452
SE|167592||ab|1|entity|C0449913|System|ftcn|||systems|||0|901|453|460
SE|167592||ab|1|entity|C0024400|Macaca mulatta|mamm|||rhesus monkey|||0|901|501|514
SE|167592||ab|1|relation|0|0|C0017932|Glycogen (Starch) Synthase|aapp,gngm,enzy|gngm|||glycogen synthase|||0|901|408|425|MOD/HEAD|PART_OF||400|425|0|0|C0205054|Hepatic|blor|blor|||hepatic|||0|901|400|407
SE|167592||ab|1|relation|6|4|C0017687|Glucagon|aapp,gngm,horm,nsba,phsu|aapp|2641|GCG|glucagon|||0|694|360|368|PREP|TREATS||475|477|1|1|C0024400|Macaca mulatta|mamm|mamm|||rhesus monkey|||0|901|501|514
SE|167592||ab|1|relation|6|4|C0021641|Insulin|aapp,gngm,horm,phsu|horm|||insulin|||0|1000|348|355|PREP|TREATS||475|477|1|1|C0024400|Macaca mulatta|mamm|mamm|||rhesus monkey|||0|901|501|514
SE|167592||ab|1|relation|6|4|C0357164|Parenteral form glucose|carb,phsu|phsu|||intravenous glucose|||0|1000|327|346|PREP|TREATS||475|477|1|1|C0024400|Macaca mulatta|mamm|mamm|||rhesus monkey|||0|901|501|514

SE|167592||ab|2|text|516|673|Results were correlated with measurements of hepatic        cyclic AMP (cAMP) concentrations and plasma glucose, insulin, and glucagon       concentrations.
SE|167592||ab|2|entity|C1274040|result|ftcn|||Results|||0|966|516|523
SE|167592||ab|2|entity|C0242485|Measurement|ftcn|||measurements|||0|1000|545|557
SE|167592||ab|2|entity|C0205054|Hepatic|blor|||hepatic|||0|861|561|568
SE|167592||ab|2|entity|C0001455|Cyclic AMP|bacs,nnon|||cyclic AMP|||0|861|576|586
SE|167592||ab|2|entity|C0032105|Plasma|bdsu|||plasma|||0|888|613|619
SE|167592||ab|2|entity|C0017725|Glucose|bacs,carb,phsu|||glucose|||0|888|620|627
SE|167592||ab|2|entity|C0021641|Insulin|aapp,horm,phsu|||insulin|||0|1000|629|636
SE|167592||ab|2|entity|C0017687|Glucagon|aapp,horm,nsba,phsu|2641|GCG|glucagon|||0|888|642|650
SE|167592||ab|2|relation|0|0|C0032105|Plasma|bdsu|bdsu|||plasma|||0|888|613|619|MOD/HEAD|LOCATION_OF||613|627|0|0|C0017725|Glucose|bacs,carb,phsu|bacs|||glucose|||0|888|620|627

SE|167592||ab|3|text|673|845|Both glucose and insulin administration promoted significant       inactivation of phosphorylase by 1 min, which was followed by more gradual       activation of synthase.
SE|167592||ab|3|entity|C0017725|Glucose|bacs,carb,phsu|||glucose|||0|1000|678|685
SE|167592||ab|3|entity|C0021641|Insulin|aapp,horm,phsu|||insulin|||0|888|690|697
SE|167592||ab|3|entity|C0750502|Significant|idcn|||significant|||0|888|722|733
SE|167592||ab|3|entity|C0544461|Inactivation|comd|||inactivation|||0|888|740|752
SE|167592||ab|3|entity|C0917783|Glycogen Phosphorylase, Muscle Form|aapp,enzy|||phosphorylase|||0|1000|756|769
SE|167592||ab|3|entity|C0439232|Minute of time|tmco|||min|||0|861|775|778
SE|167592||ab|3|entity|C0205172|More|ftcn|||more|||0|623|802|806
SE|167592||ab|3|entity|C0439833|Gradual|qlco|||gradual|||0|623|807|814
SE|167592||ab|3|relation|2|2|C0017725|Glucose|bacs,carb,phsu|bacs|||glucose|||0|1000|678|685|VERB|PREDISPOSES||713|721|5|1|C0544461|Inactivation|comd|comd|||inactivation|||0|888|740|752
SE|167592||ab|3|relation|2|2|C0021641|Insulin|aapp,gngm,horm,phsu|phsu|||insulin|||0|888|690|697|VERB|PREDISPOSES||713|721|5|1|C0544461|Inactivation|comd|comd|||inactivation|||0|888|740|752

SE|167592||ab|4|text|845|923|Neither glucose nor insulin caused significant changes in       hepatic cAMP.
SE|167592||ab|4|entity|C0017725|Glucose|bacs,carb,phsu|||glucose|||1|1000|853|860
SE|167592||ab|4|entity|C0021641|Insulin|aapp,horm,phsu|||insulin|||1|1000|865|872
SE|167592||ab|4|entity|C0750502|Significant|idcn|||significant|||0|872|880|891
SE|167592||ab|4|entity|C0205054|Hepatic|blor|||hepatic|||0|901|909|916
SE|167592||ab|4|entity|C0001455|Cyclic AMP|bacs,nnon|||cAMP|||0|901|917|921
SE|167592||ab|4|relation|3|2|C0017725|Glucose|bacs,carb,phsu|phsu|||glucose|||1|1000|853|860|PREP|COEXISTS_WITH|negation|900|902|1|1|C0001455|Cyclic AMP|bacs,nnon|bacs|||cAMP|||0|901|917|921
SE|167592||ab|4|relation|3|2|C0021641|Insulin|aapp,gngm,horm,phsu|aapp|||insulin|||1|1000|865|872|PREP|COEXISTS_WITH|negation|900|902|1|1|C0001455|Cyclic AMP|bacs,nnon|bacs|||cAMP|||0|901|917|921

SE|167592||ab|5|text|923|1179|Marked hyperglucagonemia resulting from insulin-induced       hypoglycemia did not cause increases IN in hepatic cAMP, suggesting that the       elevated insulin levels possibly inhibited glucagon action on the hepatic       adenylate cyclase-cAMP system.
SE|167592||ab|5|entity|C0522501|Massive|qlco|||Marked|||0|888|923|929
SE|167592||ab|5|entity|C0342218|Excessive glucagon secretion|patf|||hyperglucagonemia|||0|888|930|947
SE|167592||ab|5|entity|C0205263|Induced|ftcn|||induced|||0|901|971|978
SE|167592||ab|5|entity|C0858734|Insulin hypoglycemia|dsyn|||insulin-induced       hypoglycemia|||0|901|963|997
SE|167592||ab|5|entity|C1518422|Not|ftcn|||not|||0|1000|1002|1005
SE|167592||ab|5|entity|C0442805|Increase|ftcn|||increases|||0|966|1012|1021
SE|167592||ab|5|entity|C0205054|Hepatic|blor|||hepatic|||0|901|1028|1035
SE|167592||ab|5|entity|C0001455|Cyclic AMP|bacs,nnon|||cAMP|||0|901|1036|1040
SE|167592||ab|5|entity|C0205250|High|qlco|||elevated|||0|890|1068|1076
SE|167592||ab|5|entity|C0202098|Insulin measurement|lbpr|||insulin levels|||0|890|1077|1091
SE|167592||ab|5|entity|C0332149|Possible|qlco|||possibly|||0|1000|1092|1100
SE|167592||ab|5|entity|C0017687|Glucagon|aapp,horm,nsba,phsu|2641|GCG|glucagon|||0|694|1111|1119
SE|167592||ab|5|entity|C0205054|Hepatic|blor|||hepatic|||0|839|1134|1141
SE|167592||ab|5|entity|C0001492|Adenylate Cyclase|aapp,enzy|||adenylate cyclase|||0|839|1148|1165
SE|167592||ab|5|entity|C0001455|Cyclic AMP|bacs,nnon|||cAMP|||0|839|1166|1170
SE|167592||ab|5|entity|C0449913|System|ftcn|||system|||0|839|1171|1177
SE|167592||ab|5|relation|5|2|C0001455|Cyclic AMP|bacs,nnon|bacs|||cAMP|||0|901|1036|1040|NOM|INTERACTS_WITH||1120|1126|5|0|C0017687|Glucagon|aapp,gngm,horm,nsba,phsu|aapp|2641|GCG|glucagon|||0|694|1111|1119
SE|167592||ab|5|relation|6|1|C0858734|Insulin hypoglycemia|dsyn|dsyn|||insulin-induced       hypoglycemia|||0|901|963|997|VERB|CAUSES||948|957|1|1|C0342218|Excessive glucagon secretion|patf|patf|||hyperglucagonemia|||0|888|930|947

SE|167592||ab|6|text|1179|1407|Glucagon administration caused large increases in        hepatic cAMP and activation of phosphorylase within 1 min, followed by more       gradual inactivation of synthase when it had been previously activated by       glucose.
SE|167592||ab|6|entity|C0017687|Glucagon|aapp,horm,nsba,phsu|2641|GCG|Glucagon|||0|888|1179|1187
SE|167592||ab|6|entity|C0549177|Large|qnco|||large|||0|872|1210|1215
SE|167592||ab|6|entity|C0442805|Increase|ftcn|||increases|||0|872|1216|1225
SE|167592||ab|6|entity|C0205054|Hepatic|blor|||hepatic|||0|901|1236|1243
SE|167592||ab|6|entity|C0001455|Cyclic AMP|bacs,nnon|||cAMP|||0|901|1244|1248
SE|167592||ab|6|entity|C0917783|Glycogen Phosphorylase, Muscle Form|aapp,enzy|||phosphorylase|||0|1000|1267|1280
SE|167592||ab|6|entity|C0439232|Minute of time|tmco|||min|||0|861|1290|1293
SE|167592||ab|6|entity|C0205172|More|ftcn|||more|||0|851|1307|1311
SE|167592||ab|6|entity|C0439833|Gradual|qlco|||gradual|||0|851|1318|1325
SE|167592||ab|6|entity|C0544461|Inactivation|comd|||inactivation|||0|851|1326|1338
SE|167592||ab|6|entity|C0017725|Glucose|bacs,carb,phsu|||glucose|||0|1000|1398|1405
SE|167592||ab|6|relation|1|1|C0017725|Glucose|bacs,carb,phsu|bacs|||glucose|||0|1000|1398|1405|VERB|STIMULATES||1379|1388|8|4|C0917783|Glycogen Phosphorylase, Muscle Form|aapp,gngm,enzy|gngm|||phosphorylase|||0|1000|1267|1280

SE|167592||ab|7|text|1407|1700|Concomitant glucose infusion, with resulting increased plasma insulin       concentrations, markedly diminished the duration of hepatic cAMP elevations       following glucagon adminstration, again suggesting an insulin inhibition of       glucagon action on the hepatic adenylate-cAMP system.
SE|167592||ab|7|entity|C1516780|Concomitant|qlco|||Concomitant|||0|851|1407|1418
SE|167592||ab|7|entity|C0017725|Glucose|bacs,carb,phsu|||glucose|||0|851|1419|1426
SE|167592||ab|7|entity|C0574032|Infusion procedures|topp|||infusion|||0|851|1427|1435
SE|167592||ab|7|entity|C1274040|result|ftcn|||resulting|||0|833|1442|1451
SE|167592||ab|7|entity|C0205217|Increased|qnco|||increased|||0|833|1452|1461
SE|167592||ab|7|entity|C0857690|Plasma insulin|lbpr|||plasma insulin|||0|833|1462|1476
SE|167592||ab|7|entity|C0522501|Massive|qlco|||markedly|||0|1000|1499|1507
SE|167592||ab|7|entity|C0449238|Duration|tmco|||duration|||0|1000|1523|1531
SE|167592||ab|7|entity|C0205054|Hepatic|blor|||hepatic|||0|850|1535|1542
SE|167592||ab|7|entity|C0001455|Cyclic AMP|bacs,nnon|||cAMP|||0|850|1543|1547
SE|167592||ab|7|entity|C0702240|Elevation|spco|||elevations|||0|850|1548|1558
SE|167592||ab|7|entity|C0017687|Glucagon|aapp,horm,nsba,phsu|2641|GCG|glucagon|||0|694|1575|1583
SE|167592||ab|7|entity|C0021641|Insulin|aapp,horm,phsu|||insulin|||0|888|1619|1626
SE|167592||ab|7|entity|C0017687|Glucagon|aapp,horm,nsba,phsu|2641|GCG|glucagon|||0|694|1647|1655
SE|167592||ab|7|entity|C0205054|Hepatic|blor|||hepatic|||0|840|1670|1677
SE|167592||ab|7|entity|C0597765|adenylate|bacs,nnon|||adenylate|||0|840|1678|1687
SE|167592||ab|7|entity|C0001455|Cyclic AMP|bacs,nnon|||cAMP|||0|840|1688|1692
SE|167592||ab|7|entity|C0449913|System|ftcn|||system|||0|840|1693|1699
SE|167592||ab|7|relation|3|3|C0017725|Glucose|bacs,carb,phsu|bacs|||glucose|||0|851|1419|1426|NOM|STIMULATES||1548|1558|3|0|C0001455|Cyclic AMP|bacs,nnon|bacs|||cAMP|||0|850|1543|1547
SE|167592||ab|7|relation|5|5|C0017725|Glucose|bacs,carb,phsu|bacs|||glucose|||0|851|1419|1426|NOM|INHIBITS||1627|1637|5|0|C0021641|Insulin|aapp,gngm,horm,phsu|gngm|||insulin|||0|888|1619|1626
SE|167592||ab|7|relation|6|6|C0017725|Glucose|bacs,carb,phsu|bacs|||glucose|||0|851|1419|1426|NOM|INTERACTS_WITH||1656|1662|6|0|C0017687|Glucagon|aapp,gngm,horm,nsba,phsu|aapp|2641|GCG|glucagon|||0|694|1647|1655

